Procept Biorobotics (PRCT) financial statements
Procept Biorobotics reported revenue of $308M in fiscal 2025, up 109.0% a year over 5 years.
Net income was -$96M and the operating margin -33.7%, against -619.4% in 2020.
Free cash flow was -$58M.
The diluted share count rose 1416% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Procept Biorobotics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8M | $34M | $75M | $136M | $224M | $308M |
| Cost of revenue | $9M | $19M | $38M | $65M | $87M | $112M |
| Gross profit | -$1M | $16M | $37M | $71M | $137M | $196M |
| Research and development | $16M | $19M | $29M | $48M | $62M | $71M |
| Selling, general and admin | $30M | $51M | $89M | $132M | $171M | $229M |
| Operating income | -$48M | -$54M | -$81M | -$109M | -$97M | -$104M |
| Interest expense | $5M | $6M | $5M | $4M | $4M | $4M |
| Pre-tax income | — | — | — | -$106M | -$91M | -$95M |
| Income tax | $0 | $0 | $0 | $80,000 | $368,000 | $190,000 |
| Net income | -$53M | -$60M | -$87M | -$106M | -$91M | -$96M |
| EPS (diluted) | -$14.47 | -$3.63 | -$1.96 | -$2.24 | -$1.75 | -$1.72 |
| Diluted shares | 4M | 16M | 44M | 47M | 52M | 56M |
| Gross margin | -16.3% | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Operating margin | -619.4% | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Net margin | -687.0% | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
Balance sheet
Fiscal years, from Procept Biorobotics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $100M | $304M | $222M | $257M | $334M | $287M |
| Receivables | $2M | $4M | $15M | $48M | $83M | $84M |
| Inventory | $7M | $13M | $29M | $40M | $56M | $71M |
| Total current assets | $110M | $326M | $273M | $351M | $482M | $450M |
| Property, plant and equipment | $8M | $5M | $9M | $29M | $27M | $30M |
| Total assets | $126M | $337M | $309M | $405M | $534M | $508M |
| Total current liabilities | $15M | $16M | $35M | $46M | $53M | $66M |
| Long-term debt | $44M | $50M | $51M | $51M | $51M | $52M |
| Total liabilities | $65M | $70M | $112M | $124M | $132M | $142M |
| Shareholders' equity | -$183M | $267M | $197M | $281M | $402M | $366M |
| Net debt | -$51M | -$254M | -$171M | -$206M | -$282M | -$235M |
Cash flow
Fiscal years, from Procept Biorobotics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$48M | -$57M | -$80M | -$108M | -$99M | -$49M |
| Capital spending | $233,000 | $592,000 | $3M | $25M | $4M | $9M |
| Free cash flow | -$49M | -$58M | -$83M | -$133M | -$104M | -$58M |
| Stock-based compensation | $2M | $4M | $10M | $19M | $32M | $48M |
| Net borrowing | — | $0 | -$50M | $0 | $0 | — |
| Free cash flow margin | -629.5% | -168.0% | -110.7% | -97.8% | -46.2% | -18.9% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PRCT.
Open PRCT in InvestinglyQuestions
What was Procept Biorobotics's revenue in 2025?
$308M in fiscal 2025, from its 10-K filing.
How much free cash flow does Procept Biorobotics generate?
-$58M in fiscal 2025 (operating cash flow minus capital spending).
From Procept Biorobotics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.